{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:32:54Z","timestamp":1790353974169,"version":"4.1.0"},"reference-count":235,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kazan Federal University Strategic Academic Leadership Program","award":["PRIORITY-2030"],"award-info":[{"award-number":["PRIORITY-2030"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Melanoma is a malignant, highly metastatic neoplasm showing increasing morbidity and mortality. Tumor invasion and angiogenesis are based on remodeling of the extracellular matrix (ECM). Selective inhibition of functional components of cell\u2013ECM interaction, such as hyaluronic acid (HA), matrix metalloproteinases (MMPs), and integrins, may inhibit tumor progression and enhance the efficacy of combination treatment with immune checkpoint inhibitors (ICIs), chemotherapy, or immunotherapy. In this review, we combine the results of different approaches targeting extracellular matrix elements in melanoma in preclinical and clinical studies. The identified limitations of many approaches, including side effects, low selectivity, and toxicity, indicate the need for further studies to optimize therapy. Nevertheless, significant progress in expanding our understanding of tumor biology and the development of targeted therapies holds great promise for the early approaches developed several decades ago to inhibit metastasis through ECM targeting.<\/jats:p>","DOI":"10.3390\/cells13221917","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T07:51:15Z","timestamp":1732002675000},"page":"1917","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-4590","authenticated-orcid":false,"given":"Yuriy P.","family":"Mayasin","sequence":"first","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4196-4052","authenticated-orcid":false,"given":"Maria N.","family":"Osinnikova","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0326-3450","authenticated-orcid":false,"given":"Chulpan B.","family":"Kharisova","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0704-8141","authenticated-orcid":false,"given":"Kristina V.","family":"Kitaeva","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-0527","authenticated-orcid":false,"given":"Ivan Y.","family":"Filin","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5743-9692","authenticated-orcid":false,"given":"Anna V.","family":"Gorodilova","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorii I.","family":"Kutovoi","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8776-3662","authenticated-orcid":false,"given":"Valeriya V.","family":"Solovyeva","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatolii I.","family":"Golubev","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9427-5739","authenticated-orcid":false,"given":"Albert A.","family":"Rizvanov","sequence":"additional","affiliation":[{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia"},{"name":"Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420111 Kazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Strashilov, S., and Yordanov, A. (2021). Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126395"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neo.2021.11.013","article-title":"Spatiotemporal Trends of the Global Burden of Melanoma in 204 Countries and Territories from 1990 to 2019: Results from the 2019 Global Burden of Disease Study","volume":"24","author":"Li","year":"2022","journal-title":"Neoplasia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/dermatopathology10010013","article-title":"Histopathological Diagnosis of Malignant Melanoma at the Dawn of 2023: Knowledge Gained and New Challenges","volume":"10","author":"Cazzato","year":"2023","journal-title":"Dermatopathology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/1940-6207.CAPR-11-0460","article-title":"Risk Factors for Malignant Melanoma in White and Non-White\/Non-African American Populations: The Multiethnic Cohort","volume":"5","author":"Park","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41419-017-0059-7","article-title":"Cell Death-Based Treatments of Melanoma:Conventional Treatments and New Therapeutic Strategies","volume":"9","author":"Mattia","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-017-0320-y","article-title":"Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond","volume":"19","author":"Zhou","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.suc.2019.09.013","article-title":"Principles of Targeted Therapy for Melanoma","volume":"100","author":"Sun","year":"2020","journal-title":"Surg. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14740338.2019.1607289","article-title":"Update on BRAF and MEK Inhibition for Treatment of Melanoma in Metastatic, Unresectable, and Adjuvant Settings","volume":"18","author":"Broman","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., and Milella, M. (2020). Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12102870"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kharouf, N., Flanagan, T.W., Hassan, S.-Y., Shalaby, H., Khabaz, M., Hassan, S.-L., Megahed, M., Haikel, Y., Santourlidis, S., and Hassan, M. (2023). Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment. Cancers, 15.","DOI":"10.3390\/cancers15123147"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1590\/abd1806-4841.20176183","article-title":"Melanoma: Tumor Microenvironment and New Treatments","volume":"92","author":"Festa","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/1078-0432.CCR-07-1562","article-title":"Combining Agents That Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy","volume":"14","author":"Blansfield","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.hoc.2020.08.012","article-title":"Adjuvant Therapy of Melanoma","volume":"35","author":"Tarhini","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11523-021-00840-3","article-title":"The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges","volume":"16","author":"Stege","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/EDBK_349411","article-title":"Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease","volume":"42","author":"Mittendorf","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/jnci\/djaa217","article-title":"Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?","volume":"113","author":"Bilusic","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant Dabrafenib Combined with Trametinib for Resectable, Stage IIIB-C, BRAFV600 Mutation-Positive Melanoma (NeoCombi): A Single-Arm, Open-Label, Single-Centre, Phase 2 Trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41389-023-00452-8","article-title":"The Mechanical Phenotypic Plasticity of Melanoma Cell: An Emerging Driver of Therapy Cross-Resistance","volume":"12","author":"Diazzi","year":"2023","journal-title":"Oncogenesis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning Cold into Hot: Firing up the Tumor Microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/0008-5472.CAN-12-0122","article-title":"Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy","volume":"72","author":"Swartz","year":"2012","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cac2.12316","article-title":"The Theory of Tumor Ecosystem","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.7150\/thno.82690","article-title":"Nasopharyngeal Carcinoma Ecology Theory: Cancer as Multidimensional Spatiotemporal \u201cUnity of Ecology and Evolution\u201d Pathological Ecosystem","volume":"13","author":"Luo","year":"2023","journal-title":"Theranostics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101417","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast Heterogeneity in Tumor Micro-Environment: Role in Immunosuppression and New Therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Monteran, L., and Erez, N. (2019). The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01835"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gao, J., Liang, Y., and Wang, L. (2022). Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.888713"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Scott, E.N., Gocher, A.M., Workman, C.J., and Vignali, D.A.A. (2021). Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.702726"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chaudhary, B., and Elkord, E. (2016). Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, 4.","DOI":"10.3390\/vaccines4030028"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-Talk between Myeloid-Derived Suppressor Cells (MDSC), Macrophages, and Dendritic Cells Enhances Tumor-Induced Immune Suppression","volume":"22","author":"Sinha","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., and Umansky, V. (2018). Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00398"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00262-011-1181-5","article-title":"Immune Suppression in the Tumor Microenvironment: A Role for Dendritic Cell-Mediated Tolerization of T Cells","volume":"61","author":"Hurwitz","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1189\/jlb.5MR1216-508R","article-title":"Neutrophils as Active Regulators of the Immune System in the Tumor Microenvironment","volume":"102","author":"Shaul","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57622","DOI":"10.18632\/oncotarget.18038","article-title":"The fat and the bad: Mature adipocytes, key actors in tumor progression and resistance","volume":"8","author":"Duong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4939-9095-5_15","article-title":"Tumorigenic Interplay Between Macrophages and Collagenous Matrix in the Tumor Microenvironment","volume":"1944","author":"Varol","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15384047.2017.1394538","article-title":"Modulating Secreted Components of Tumor Microenvironment: A Masterstroke in Tumor Therapeutics","volume":"19","author":"Patel","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.matbio.2017.10.003","article-title":"Extracellular Vesicles Are Integral and Functional Components of the Extracellular Matrix","volume":"75\u201376","author":"Rilla","year":"2019","journal-title":"Matrix Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1042\/BST20200717","article-title":"Extracellular Vesicles and the Extracellular Matrix: A New Paradigm or Old News?","volume":"48","author":"Lewin","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Al Halawani, A., Mithieux, S.M., Yeo, G.C., Hosseini-Beheshti, E., and Weiss, A.S. (2022). Extracellular Vesicles: Interplay with the Extracellular Matrix and Modulated Cell Responses. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063389"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Lattmann, E., and Levesque, M.P. (2022). The Role of Extracellular Vesicles in Melanoma Progression. Cancers, 14.","DOI":"10.3390\/cancers14133086"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Benito-Mart\u00edn, A., Jasiulionis, M.G., and Garc\u00eda-Silva, S. (2023). Extracellular Vesicles and Melanoma: New Perspectives on Tumor Microenvironment and Metastasis. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1061982"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2019.06.020","article-title":"Natural Melanoma-Derived Extracellular Vesicles","volume":"59","author":"Hood","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Palmulli, R., Bresteau, E., Raposo, G., Montagnac, G., and van Niel, G. (2023). In Vitro Interaction of Melanoma-Derived Extracellular Vesicles with Collagen. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043703"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kluszczynska, K., and Czyz, M. (2023). Extracellular Vesicles-Based Cell-Cell Communication in Melanoma: New Perspectives in Diagnostics and Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24020965"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201102147","article-title":"The Extracellular Matrix: A Dynamic Niche in Cancer Progression","volume":"196","author":"Lu","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12307-014-0150-x","article-title":"Stroma as an Active Player in the Development of the Tumor Microenvironment","volume":"8","author":"Vannucci","year":"2015","journal-title":"Cancer Microenviron."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/jcb.27681","article-title":"Extracellular Matrix (ECM) Stiffness and Degradation as Cancer Drivers","volume":"120","author":"Najafi","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Brassart-Pasco, S., Br\u00e9zillon, S., Brassart, B., Ramont, L., Oudart, J.-B., and Monboisse, J.C. (2020). Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00397"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.semcancer.2019.09.004","article-title":"Emerging Roles of ECM Remodeling Processes in Cancer","volume":"62","author":"Mohan","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Patras, L., Paul, D., and Matei, I.R. (2023). Weaving the Nest: Extracellular Matrix Roles in Pre-Metastatic Niche Formation. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1163786"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"C955","DOI":"10.1152\/ajpcell.00326.2015","article-title":"Structural ECM Components in the Premetastatic and Metastatic Niche","volume":"310","author":"Erler","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10585-008-9209-8","article-title":"Three-Dimensional Context Regulation of Metastasis","volume":"26","author":"Erler","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/cas.13554","article-title":"Periostin Antisense Oligonucleotide Suppresses Bleomycin-Induced Formation of a Lung Premetastatic Niche for Melanoma","volume":"109","author":"Semba","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","article-title":"Preparing the \u201cSoil\u201d: The Premetastatic Niche","volume":"66","author":"Kaplan","year":"2006","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jaad.2017.06.149","article-title":"A Meta-Analysis of Nevus-Associated Melanoma: Prevalence and Practical Implications","volume":"77","author":"Pampena","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ad.2017.06.009","article-title":"Melanoma Arising in a Melanocytic Nevus","volume":"109","author":"Nagore","year":"2018","journal-title":"Actas Dermosifiliogr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/1547691X.2012.723767","article-title":"Microenvironment and Tumor Progression of Melanoma: New Therapeutic Prospectives","volume":"10","author":"Botti","year":"2013","journal-title":"J. Immunotoxicol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Watt, F.M., and Fujiwara, H. (2011). Cell-Extracellular Matrix Interactions in Normal and Diseased Skin. Cold Spring Harb. Perspect. Biol., 3.","DOI":"10.1101\/cshperspect.a005124"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2559.1994.tb01268.x","article-title":"The Extracellular Matrix in Pigmented Skin Lesions: An Immunohistochemical Study","volume":"24","author":"Fleuren","year":"1994","journal-title":"Histopathology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00008390-200506000-00004","article-title":"Immunohistochemical investigation of \u03b11 (IV) and \u03b15 (IV) collagen chains in a broad spectrum of melanocytic tumours","volume":"15","author":"Quatresooz","year":"2005","journal-title":"Melanoma Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0955-0674(02)00375-7","article-title":"Versican: A Versatile Extracellular Matrix Proteoglycan in Cell Biology","volume":"14","author":"Wight","year":"2002","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: Wounds That Do Not Heal. Similarities between Tumor Stroma Generation and Wound Healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0959-8049(97)00231-1","article-title":"Stochastic Relationship between the Growth Fraction and Vascularity of Thin Malignant Melanomas","volume":"33","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4161\/cbt.1.5.158","article-title":"Cellular Adhesion Pathways and Metastatic Potential of Human Melanoma","volume":"1","author":"McGary","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00000372-199608000-00005","article-title":"Quantitative Morphology of Collagen Fibers in Cutaneous Malignant Melanoma and Melanocytic Nevus","volume":"18","author":"Smolle","year":"1996","journal-title":"Am. J. Dermatopathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The Extracellular Matrix Modulates the Hallmarks of Cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1158\/1538-7445.AM2024-4148","article-title":"Abstract 4148: Extracellular Matrix Biophysical Properties Change during Nevus to Melanoma Progression","volume":"84","author":"Kavuturu","year":"2024","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1158\/0008-5472.CAN-06-3312","article-title":"Mutant V600E BRAF Increases Hypoxia Inducible Factor-1\u03b1 Expression in Melanoma","volume":"67","author":"Kumar","year":"2007","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-13-0005","article-title":"Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2","volume":"3","author":"Marchbank","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101335","DOI":"10.1016\/j.tranon.2021.101335","article-title":"SNF5, a Core Subunit of SWI\/SNF Complex, Regulates Melanoma Cancer Cell Growth, Metastasis, and Immune Escape in Response to Matrix Stiffness","volume":"17","author":"Chen","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Br\u00e1s, M.M., Radmacher, M., Sousa, S.R., and Granja, P.L. (2020). Melanoma in the Eyes of Mechanobiology. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00054"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1021\/acschembio.8b00396","article-title":"In Situ Drug Delivery to Breast Cancer-Associated Extracellular Matrix","volume":"13","author":"Fleming","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jalil, S.M.A., Henry, J.C., and Cameron, A.J.M. (2024). Targets in the Tumour Matrisome to Promote Cancer Therapy Response. Cancers, 16.","DOI":"10.3390\/cancers16101847"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tokuda, E.Y., Leight, J.L., and Anseth, K.S. (2014). Modulation of Matrix Elasticity with PEG Hydrogels to Study Melanoma Drug Responsiveness. Biomaterials, 35.","DOI":"10.1016\/j.biomaterials.2014.01.063"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1038\/onc.2009.299","article-title":"Matrix Density-Induced Mechanoregulation of Breast Cell Phenotype, Signaling and Gene Expression through a FAK\u2013ERK Linkage","volume":"28","author":"Provenzano","year":"2009","journal-title":"Oncogene"},{"key":"ref_76","first-page":"3617","article-title":"Changes in Structure and Stiffness of the Lung Extracellular Matrix in Lung Cancer","volume":"60","author":"Narciso","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Narciso, M., Mart\u00ednez, \u00c1., J\u00fanior, C., D\u00edaz-Valdivia, N., Ulldemolins, A., Berardi, M., Neal, K., Navajas, D., Farr\u00e9, R., and Alcaraz, J. (2023). Lung Micrometastases Display ECM Depletion and Softening While Macrometastases Are 30-Fold Stiffer and Enriched in Fibronectin. Cancers, 15.","DOI":"10.3390\/cancers15082404"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2174\/092986706777935230","article-title":"Development of Heparanase Inhibitors for Anti-Cancer Therapy","volume":"13","author":"Miao","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Yuan, F., Yang, Y., Zhou, H., Quan, J., Liu, C., Wang, Y., Zhang, Y., and Yu, X. (2022). Heparanase in Cancer Progression: Structure, Substrate Recognition and Therapeutic Potential. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.926353"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12967-020-02624-1","article-title":"Heparanase and the Hallmarks of Cancer","volume":"18","author":"Jayatilleke","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"74678","DOI":"10.18632\/oncotarget.12492","article-title":"The prognostic significance of heparanase expression in metastatic melanoma","volume":"7","author":"Vornicova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_82","first-page":"345","article-title":"Selective Heparanase Localization in Malignant Melanoma","volume":"26","author":"Murry","year":"2005","journal-title":"Int. J. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1016\/S0021-9258(18)92871-1","article-title":"Suramin. A Potent Inhibitor of Melanoma Heparanase and Invasion","volume":"266","author":"Nakajima","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bmcl.2005.09.069","article-title":"1-[4-(1H-Benzoimidazol-2-Yl)-Phenyl]-3-[4-(1H-Benzoimidazol-2-Yl)-Phenyl]-Urea Derivatives as Small Molecule Heparanase Inhibitors","volume":"16","author":"Pan","year":"2006","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1021\/bi00366a050","article-title":"Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo-Beta-Glucuronidase (Heparanase) of Metastatic Melanoma Cells","volume":"25","author":"Irimura","year":"1986","journal-title":"Biochemistry"},{"key":"ref_86","first-page":"290","article-title":"Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin","volume":"14","author":"Vlodavsky","year":"1994","journal-title":"Invasion Metastasis"},{"key":"ref_87","first-page":"106","article-title":"Structural Requirements for Inhibition of Melanoma Lung Colonization by Heparanase Inhibiting Species of Heparin","volume":"31","author":"Bitan","year":"1995","journal-title":"Isr. J. Med. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1381612826666201113105250","article-title":"Heparanase Inhibitors in Cancer Progression: Recent Advances","volume":"27","author":"Kaur","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.isci.2019.04.034","article-title":"Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds","volume":"15","author":"Mohan","year":"2019","journal-title":"iScience"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/978-3-030-34521-1_19","article-title":"PI-88 and Related Heparan Sulfate Mimetics","volume":"1221","author":"Chhabra","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00280-008-0712-z","article-title":"A Phase I Pharmacological and Biological Study of PI-88 and Docetaxel in Patients with Advanced Malignancies","volume":"63","author":"Chow","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0959-8049(02)80886-3","article-title":"A Phase I Study of the Heparanase Inhibitor PI-88 given Subcutaneously (Sq) in Patients (Pts) with Advanced Solid Malignancies","volume":"38","author":"Holden","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdf117","article-title":"Treatment with the Novel Anti-Angiogenic Agent PI-88 Is Associated with Immune-Mediated Thrombocytopenia","volume":"13","author":"Rosenthal","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1200\/jco.2007.25.18_suppl.8532","article-title":"Final Results of a Phase I Study of Daily PI-88 as a Single Agent and in Combination with Dacarbazine (D) in Patients with Metastatic Melanoma","volume":"25","author":"Millward","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1158\/1078-0432.CCR-05-2423","article-title":"A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors","volume":"12","author":"Basche","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10637-007-9080-5","article-title":"A Phase II Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Melanoma","volume":"26","author":"Lewis","year":"2008","journal-title":"Investig. New Drugs"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Lanzi, C., and Cassinelli, G. (2018). Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity. Molecules, 23.","DOI":"10.3390\/molecules23112915"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s10637-009-9245-5","article-title":"The PG500 Series: Novel Heparan Sulfate Mimetics as Potent Angiogenesis and Heparanase Inhibitors for Cancer Therapy","volume":"28","author":"Dredge","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Mohamed, S., and Coombe, D.R. (2017). Heparin Mimetics: Their Therapeutic Potential. Pharmaceuticals, 10.","DOI":"10.3390\/ph10040078"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1021\/jm901449m","article-title":"Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth","volume":"53","author":"Johnstone","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ejca.2015.02.007","article-title":"PG545 Enhances Anti-Cancer Activity of Chemotherapy in Ovarian Models and Increases Surrogate Biomarkers Such as VEGF in Preclinical and Clinical Plasma Samples","volume":"51","author":"Winterhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e006136","DOI":"10.1136\/jitc-2022-006136","article-title":"Phase Ib Open-Label, Multicenter Study of Pixatimod, an Activator of TLR9, in Combination with Nivolumab in Subjects with Microsatellite-Stable Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma and Other Solid Tumors","volume":"11","author":"Lemech","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1593\/neo.04493","article-title":"Antisense-Mediated Suppression of Heparanase Gene Inhibits Melanoma Cell Invasion","volume":"7","author":"Roy","year":"2005","journal-title":"Neoplasia"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Liu, X., Fang, H., Chen, H., Jiang, X., Fang, D., Wang, Y., and Zhu, D. (2012). An Artificial miRNA against HPSE Suppresses Melanoma Invasion Properties, Correlating with a down-Regulation of Chemokines and MAPK Phosphorylation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038659"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/jnci\/djh230","article-title":"Heparanase Gene Silencing, Tumor Invasiveness, Angiogenesis, and Metastasis","volume":"96","author":"Edovitsky","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_106","unstructured":"Reunanen, N., and K\u00e4h\u00e4ri, V. (2013). Matrix Metalloproteinases in Cancer Cell Invasion. Madame Curie Bioscience Database [Internet], Landes Bioscience."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jnci\/93.3.178","article-title":"Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy","volume":"93","author":"Hidalgo","year":"2001","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","article-title":"Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures into Future Successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1523-1747.2000.00068.x","article-title":"Matrix Metalloproteinases in Human Melanoma","volume":"115","author":"Hofmann","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2174\/0929867043364018","article-title":"The Design, Structure, and Clinical Update of Small Molecular Weight Matrix Metalloproteinase Inhibitors","volume":"11","author":"Skiles","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lazar, A.M., Costea, D.O., Popp, C.G., and Mastalier, B. (2024). Skin Malignant Melanoma and Matrix Metalloproteinases: Promising Links to Efficient Therapies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147804"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Alves, R., Pires, A., Jorge, J., Bal\u00e7a-Silva, J., Gon\u00e7alves, A.C., and Sarmento-Ribeiro, A.B. (2024). Batimastat Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Hematological Tumors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084554"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0163-7258(97)00023-5","article-title":"Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat","volume":"75","author":"Rasmussen","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ijc.2910580326","article-title":"Inhibition of the Metastatic Spread and Growth of B16-BL6 Murine Melanoma by a Synthetic Matrix Metalloproteinase Inhibitor","volume":"58","author":"Chirivi","year":"1994","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1006573417179","article-title":"The Matrix Metalloproteinase Inhibitor Batimastat Inhibits Angiogenesis in Liver Metastases of B16F1 Melanoma Cells","volume":"17","author":"Wylie","year":"1999","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00210790","article-title":"Phase I Trial of a Novel Matrix Metalloproteinase Inhibitor Batimastat (BB-94) in Patients with Advanced Cancer","volume":"14","author":"Low","year":"1996","journal-title":"Investig. New Drugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1007\/s002800051099","article-title":"Marimastat (BB2516): Current Status of Development","volume":"43","author":"Steward","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_118","first-page":"493a","article-title":"Phase I-II Study of Marimastat (BB2516) in Patients with Metastatic Melanoma","volume":"16","author":"Bodurtha","year":"1997","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"ref_119","first-page":"PI99","article-title":"A Phase I and Pharmacologic Study of the Combination of Marimastat and Paclitaxel in Patients with Advanced Malignancy","volume":"9","author":"Toppmeyer","year":"2003","journal-title":"Med. Sci. Monit."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1020625423524","article-title":"Phase II Study of Marimastat (BB-2516) in Malignant Melanoma: A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group","volume":"20","author":"Quirt","year":"2002","journal-title":"Investig. New Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-04-0071","article-title":"The Matrix Metalloproteinase Inhibitor Prinomastat Enhances Photodynamic Therapy Responsiveness in a Mouse Tumor Model","volume":"64","author":"Ferrario","year":"2004","journal-title":"Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1076\/ceyr.24.2.86.8159","article-title":"The Effect of Prinomastat (AG3340), a Synthetic Inhibitor of Matrix Metalloproteinases, on Uveal Melanoma Rabbit Model","volume":"24","author":"Ozerdem","year":"2002","journal-title":"Curr. Eye Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1749-6632.1999.tb07689.x","article-title":"Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials","volume":"878","author":"Shalinsky","year":"1999","journal-title":"Ann. N. Y Acad. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1078-0432.CCR-0981-3","article-title":"Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor","volume":"10","author":"Hande","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/0929867013373516","article-title":"Cytotoxic Activity and Inhibition of Tumor Cell Invasion by Derivatives of a Chemically Modified Tetracycline CMT-3 (COL-3)","volume":"8","author":"Lokeshwar","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2001.19.2.584","article-title":"Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer","volume":"19","author":"Rudek","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10585-008-9198-7","article-title":"Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A) Inhibited Hematogenic Metastasis of B16 Melanoma Cells in Both Experimental and Spontaneous Metastasis Models","volume":"25","author":"Kasaoka","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_128","first-page":"411","article-title":"Anti-Tumor Angiogenic Effect of a Matrix Metalloproteinase Inhibitor MMI270","volume":"23","author":"Nakamura","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_129","first-page":"8480","article-title":"Inhibition of Angiogenesis and Metastasis in Two Murine Models by the Matrix Metalloproteinase Inhibitor, BMS-275291","volume":"61","author":"Naglich","year":"2001","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/14756366.2013.855207","article-title":"A Novel Matrix Metalloproteinase-2 Inhibitor Triazolylmethyl Aziridine Reduces Melanoma Cell Invasion, Angiogenesis and Targets ERK1\/2 Phosphorylation","volume":"29","author":"Romanchikova","year":"2014","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13073-020-00780-z","article-title":"Small-Molecule MMP2\/MMP9 Inhibitor SB-3CT Modulates Tumor Immune Surveillance by Regulating PD-L1","volume":"12","author":"Ye","year":"2020","journal-title":"Genome Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1021\/ol9008393","article-title":"DFT Studies of the Ring Opening Mechanism of SB-3CT, a Potent Inhibitor of Matrix Metalloproteinase 2","volume":"11","author":"Tao","year":"2009","journal-title":"Org. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1158\/0008-5472.CAN-04-3570","article-title":"Antimetastatic Activity of a Novel Mechanism-Based Gelatinase Inhibitor","volume":"65","author":"Arlt","year":"2005","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.phrs.2016.09.033","article-title":"The Thiirane-Based Selective MT1-MMP\/MMP2 Inhibitor ND-322 Reduces Melanoma Tumor Growth and Delays Metastatic Dissemination","volume":"113","author":"Marusak","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1158\/1078-0432.CCR-04-1985","article-title":"Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 3: In Vivo Evaluation of Cyclopentylcarbamoylphosphonic Acid in Experimental Metastasis and Angiogenesis","volume":"11","author":"Reich","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1359-6349(06)70208-7","article-title":"203 POSTER Antitumor Efficacy of DX-2400, a Potent and Selective Human Antibody MMP-14 Inhibitor Discovered Using Phage Display Technology","volume":"4","author":"Devy","year":"2006","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-08-3255","article-title":"Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis","volume":"69","author":"Devy","year":"2009","journal-title":"Cancer Res."},{"key":"ref_138","first-page":"e1421","article-title":"Matrix Metalloproteinases-9 as a Promising Target for Anti-Cancer Vaccine: Inhibition of Melanoma Tumor Growth in Mice Immunized with Syngeneic MMP-9 Peptides","volume":"6","author":"Roomi","year":"2019","journal-title":"World Cancer Res. J."},{"key":"ref_139","first-page":"1","article-title":"Peptide Vaccines Directed against Human Metalloproteinases (MMPs) with Anti-Tumor Efficacy In Vitro and In Vivo","volume":"1","author":"Roomi","year":"2018","journal-title":"J. Cell Med. Nat. Health"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"10849","DOI":"10.1158\/0008-5472.CAN-07-1791","article-title":"RNA Interference Inhibition of Matrix Metalloproteinase-1 Prevents Melanoma Metastasis by Reducing Tumor Collagenase Activity and Angiogenesis","volume":"67","author":"Blackburn","year":"2007","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5301\/JBM.5000026","article-title":"Potential Clinical Applications of Matrix Metalloproteinase Inhibitors and Their Future Prospects","volume":"28","author":"Li","year":"2013","journal-title":"Int. J. Biol. Markers"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/1566523024605564","article-title":"Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)","volume":"2","author":"Brand","year":"2002","journal-title":"Curr. Gene Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/37995","article-title":"Mechanism of Inhibition of the Human Matrix Metalloproteinase Stromelysin-1 by TIMP-1","volume":"389","author":"Maskos","year":"1997","journal-title":"Nature"},{"key":"ref_144","first-page":"5539","article-title":"Inhibition by Human Recombinant Tissue Inhibitor of Metalloproteinases of Human Amnion Invasion and Lung Colonization by Murine B16-F10 Melanoma Cells","volume":"48","author":"Schultz","year":"1988","journal-title":"Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00262-008-0559-5","article-title":"TIMP-1-GPI in Combination with Hyperthermic Treatment of Melanoma Increases Sensitivity to FAS-Mediated Apoptosis","volume":"58","author":"Djafarzadeh","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1248\/bpb.20.843","article-title":"Antimetastatic and Antitumor Effect of a Recombinant Human Tissue Inhibitor of Metalloproteinases-2 in Murine Melanoma Models","volume":"20","author":"Oku","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pep.2007.02.001","article-title":"A Biologically Active Angiogenesis Inhibitor, Human Serum Albumin-TIMP-2 Fusion Protein, Secreted from Saccharomyces Cerevisiae","volume":"53","author":"Kang","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.ajpath.2011.07.035","article-title":"Endogenous Angiogenesis Inhibitor Blocks Tumor Growth via Direct and Indirect Effects on Tumor Microenvironment","volume":"179","author":"Bourboulia","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.cgt.7700426","article-title":"Gene Therapy of Melanoma Pulmonary Metastasis by Intramuscular Injection of Plasmid DNA Encoding Tissue Inhibitor of Metalloproteinases-1","volume":"9","author":"Shi","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_150","first-page":"5467","article-title":"Effect of Tissue Inhibitor of the Matrix Metalloproteinases-2 Expression on the Growth and Spontaneous Metastasis of a Human Melanoma Cell Line","volume":"54","author":"Montgomery","year":"1994","journal-title":"Cancer Res."},{"key":"ref_151","first-page":"2310","article-title":"Adenovirus-Mediated Gene Delivery of Tissue Inhibitor of Metalloproteinases-3 Inhibits Invasion and Induces Apoptosis in Melanoma Cells","volume":"58","author":"Ahonen","year":"1998","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1006\/mthe.2002.0606","article-title":"Antitumor Activity and Bystander Effect of Adenovirally Delivered Tissue Inhibitor of Metalloproteinases-3","volume":"5","author":"Ahonen","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Takabe, P., Siiskonen, H., R\u00f6nk\u00e4, A., Kainulainen, K., and Pasonen-Sepp\u00e4nen, S. (2022). The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.811434"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Gagneja, S., Capalash, N., and Sharma, P. (2024). Hyaluronic Acid as a Tumor Progression Agent and a Potential Chemotherapeutic Biomolecule against Cancer: A Review on Its Dual Role. Int. J. Biol. Macromol., 275.","DOI":"10.1016\/j.ijbiomac.2024.133744"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-15-3114","article-title":"Carcinoma Cell Hyaluronan as a \u201cPortable\u201d Cancerized Prometastatic Microenvironment","volume":"76","author":"Turley","year":"2016","journal-title":"Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-09-0479","article-title":"Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities","volume":"15","author":"Toole","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Xu, Y., Benedikt, J., and Ye, L. (2024). Hyaluronic Acid Interacting Molecules Mediated Crosstalk between Cancer Cells and Microenvironment from Primary Tumour to Distant Metastasis. Cancers, 16.","DOI":"10.3390\/cancers16101907"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1039\/C9BM01636H","article-title":"Biomimetic Tissue Models Reveal the Role of Hyaluronan in Melanoma Proliferation and Invasion","volume":"8","author":"Sapudom","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/carcin\/bgi064","article-title":"Tumour Regulation of Fibroblast Hyaluronan Expression: A Mechanism to Facilitate Tumour Growth and Invasion","volume":"26","author":"Edward","year":"2005","journal-title":"Carcinogenesis"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0625.2007.00638.x","article-title":"Hyaluronan Fragments Induce Cytokine and Metalloprotease Upregulation in Human Melanoma Cells in Part by Signalling via TLR4","volume":"17","author":"Voelcker","year":"2008","journal-title":"Exp. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1523-1747.2001.00236.x","article-title":"CD44 Is the Principal Mediator of Hyaluronic-Acid-Induced Melanoma Cell Proliferation","volume":"116","author":"Ahrens","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1523-1747.1999.00804.x","article-title":"Increased Synthesis of Hyaluronate Enhances Motility of Human Melanoma Cells","volume":"113","author":"Ichikawa","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_163","first-page":"295","article-title":"Functional Roles of Hyaluronan in B16-F10 Melanoma Growth and Experimental Metastasis in Mice","volume":"2","author":"Mummert","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.yexcr.2009.03.002","article-title":"4-Methylumbelliferone Inhibits Hyaluronan Synthesis by Depletion of Cellular UDP-Glucuronic Acid and Downregulation of Hyaluronan Synthase 2 and 3","volume":"315","author":"Kultti","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.febslet.2005.03.079","article-title":"A Hyaluronan Synthase Suppressor, 4-Methylumbelliferone, Inhibits Liver Metastasis of Melanoma Cells","volume":"579","author":"Yoshihara","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bbrc.2004.07.041","article-title":"Effect of a Hyaluronan Synthase Suppressor, 4-Methylumbelliferone, on B16F-10 Melanoma Cell Adhesion and Locomotion","volume":"321","author":"Kudo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2133.2010.09699.x","article-title":"4-Methylumbelliferone Inhibits Tumour Cell Growth and the Activation of Stromal Hyaluronan Synthesis by Melanoma Cell-Derived Factors","volume":"162","author":"Edward","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1084\/jem.192.6.769","article-title":"Development of a Peptide Inhibitor of Hyaluronan-Mediated Leukocyte Trafficking","volume":"192","author":"Mummert","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01366962","article-title":"Hyaluronidase Significantly Enhances the Efficacy of Regional Vinblastine Chemotherapy of Malignant Melanoma","volume":"121","author":"Spruss","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"McGuire, J., Taguchi, T., Tombline, G., Paige, V., Janelsins, M., Gilmore, N., Seluanov, A., and Gorbunova, V. (2024). Hyaluronidase Inhibitor Delphinidin Inhibits Cancer Metastasis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64924-6"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae Drug Delivery Technology: A Novel Approach to Subcutaneous Administration Using Recombinant Human Hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant Human Hyaluronidase (rHuPH20): An Enabling Platform for Subcutaneous Drug and Fluid Administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2019.10.040","article-title":"Removal of Interstitial Hyaluronan with Recombinant Human Hyaluronidase Improves the Systemic and Lymphatic Uptake of Cetuximab in Rats","volume":"315","author":"Styles","year":"2019","journal-title":"J. Control Release"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2021.39.15_suppl.2575","article-title":"CheckMate 8KX: Phase 1\/2 Multitumor Preliminary Analyses of a Subcutaneous Formulation of Nivolumab (\u00b1 rHuPH20)","volume":"39","author":"Lonardi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"S951","DOI":"10.1016\/j.annonc.2022.07.1008","article-title":"882TiP Subcutaneous vs. Intravenous Nivolumab in Patients with Melanoma Following Complete Resection","volume":"33","author":"Ascierto","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13046-018-0763-x","article-title":"Integrins as Therapeutic Targets in the Organ-Specific Metastasis of Human Malignant Melanoma","volume":"37","author":"Huang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3892\/or.2015.3910","article-title":"Orally Active Av\u03b23 Integrin Inhibitor MK-0429 Reduces Melanoma Metastasis","volume":"33","author":"Pickarski","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.1002\/ijc.29252","article-title":"Cilengitide Downmodulates Invasiveness and Vasculogenic Mimicry of Neuropilin 1 Expressing Melanoma Cells through the Inhibition of Av\u03b25 Integrin","volume":"136","author":"Ruffini","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_179","first-page":"4499","article-title":"Role of the A5\u03b21 Integrin Receptor in the Proliferative Response of Quiescent Human Melanoma Cells to Fibronectin","volume":"52","author":"Mortarini","year":"1992","journal-title":"Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ijd.14850","article-title":"The Role of Integrins in Melanoma: A Review","volume":"59","author":"Warda","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00046839","article-title":"Structure, Function and Biological Properties of Integrin Alpha v Beta 3 on Human Melanoma Cells","volume":"10","author":"Cheresh","year":"1991","journal-title":"Cancer Metastasis Rev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1568016033477522","article-title":"Modulation of Integrin-Binding Selectivity by Mutation within the RGD-Loop of Snake Venom Proteins: A Novel Drug Development Approach","volume":"1","author":"Lu","year":"2003","journal-title":"Curr. Med. Chem. Cardiovasc. Hematol. Agents"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2174\/138161206777947713","article-title":"Integrins in Drug Targeting-RGD Templates in Toxins","volume":"12","author":"Lu","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e20230039","DOI":"10.1590\/1678-9199-jvatitd-2023-0039","article-title":"Snake Venom Disintegrins Update: Insights about New Findings","volume":"29","author":"Almeida","year":"2023","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.matbio.2013.01.001","article-title":"Inhibition of Integrins Av\/A5-Dependent Functions in Melanoma Cells by an ECD-Disintegrin Acurhagin-C","volume":"32","author":"Shih","year":"2013","journal-title":"Matrix Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijbiomac.2016.04.008","article-title":"The Disintegrin Tzabcanin Inhibits Adhesion and Migration in Melanoma and Lung Cancer Cells","volume":"88","author":"Saviola","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_187","first-page":"4993","article-title":"Contortrostatin, a Snake Venom Disintegrin, Inhibits Beta 1 Integrin-Mediated Human Metastatic Melanoma Cell Adhesion and Blocks Experimental Metastasis","volume":"54","author":"Trikha","year":"1994","journal-title":"Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/bbrc.2000.3130","article-title":"Suppressive Mechanism of Salmosin, a Novel Disintegrin in B16 Melanoma Cell Metastasis","volume":"275","author":"Kang","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00204-008-0358-y","article-title":"Colombistatin: A Disintegrin Isolated from the Venom of the South American Snake (Bothrops Colombiensis) That Effectively Inhibits Platelet Aggregation and SK-Mel-28 Cell Adhesion","volume":"83","author":"Palomar","year":"2009","journal-title":"Arch. Toxicol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.toxicon.2011.02.014","article-title":"Anti-Metastatic Activity of the Recombinant Disintegrin, r-Mojastin 1, from the Mohave Rattlesnake","volume":"57","author":"Lucena","year":"2011","journal-title":"Toxicon"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxicon.2012.03.011","article-title":"Anti-Invasive and Anti-Adhesive Activities of a Recombinant Disintegrin, r-Viridistatin 2, Derived from the Prairie Rattlesnake (Crotalus Viridis Viridis)","volume":"60","author":"Lucena","year":"2012","journal-title":"Toxicon"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.toxicon.2011.12.002","article-title":"Recombinant Rubistatin (r-Rub), an MVD Disintegrin, Inhibits Cell Migration and Proliferation, and Is a Strong Apoptotic Inducer of the Human Melanoma Cell Line SK-Mel-28","volume":"59","author":"Carey","year":"2012","journal-title":"Toxicon"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2174\/1389203716666150515125002","article-title":"Disintegrins from Snake Venoms and Their Applications in Cancer Research and Therapy","volume":"16","author":"Fox","year":"2015","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_194","first-page":"1","article-title":"Disintegrin-Like Peptides Derived from Naturally-Occurring Proteins: A Proposed Adjunct Treatment for Cancer Therapy: A Commentary","volume":"6","author":"Mizejewski","year":"2020","journal-title":"Int. J. Cancer Res. Mol. Mech."},{"key":"ref_195","first-page":"871","article-title":"In Vitro Activity of the Av\u03b23 Integrin Antagonist RGDechi-hCit on Malignant Melanoma Cells","volume":"33","author":"Pisano","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3892\/or.2012.1963","article-title":"siRNA-Mediated Silencing of Integrin \u03923 Expression Inhibits the Metastatic Potential of B16 Melanoma Cells","volume":"28","author":"Wietrzyk","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.carbpol.2016.09.034","article-title":"Bupleurum Chinense Polysaccharide Inhibit Adhesion of Human Melanoma Cells via Blocking \u03921 Integrin Function","volume":"156","author":"Tong","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijbiomac.2017.05.093","article-title":"Codonopsis Lanceolata Polysaccharide CLPS Inhibits Melanoma Metastasis via Regulating Integrin Signaling","volume":"103","author":"Liu","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_199","first-page":"e61983","article-title":"A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach","volume":"16","author":"Kothari","year":"2024","journal-title":"Cureus"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1242\/jcs.108.8.2825","article-title":"An Anti-Alpha v-Integrin Antibody That Blocks Integrin Function Inhibits the Development of a Human Melanoma in Nude Mice","volume":"108","author":"Mitjans","year":"1995","journal-title":"J. Cell Sci."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1073\/pnas.91.19.8856","article-title":"Integrin Alpha v Beta 3 Rescues Melanoma Cells from Apoptosis in Three-Dimensional Dermal Collagen","volume":"91","author":"Montgomery","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.str.2017.09.007","article-title":"The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human \u03b1V\u03b23 Integrin via Steric Hindrance","volume":"25","author":"Borst","year":"2017","journal-title":"Structure"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.1158\/1078-0432.CCR-05-0262","article-title":"Phase I Trial of a Monoclonal Antibody Specific for Av\u03b23 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion","volume":"11","author":"McNeel","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/1097-0142(20010901)92:5<1347::AID-CNCR1456>3.0.CO;2-0","article-title":"Pilot Study of Vitaxin\u2014An Angiogenesis Inhibitor\u2014In Patients with Advanced Leiomyosarcomas","volume":"92","author":"Patel","year":"2001","journal-title":"Cancer"},{"key":"ref_205","first-page":"3056","article-title":"Targeted Antiangiogenic Therapy for Cancer Using Vitaxin: A Humanized Monoclonal Antibody to the Integrin Alphavbeta3","volume":"6","author":"Gutheil","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_206","first-page":"125","article-title":"A Pilot Trial of Vitaxin, a Humanized Anti-Vitronectin Receptor (Anti Alpha v Beta 3) Antibody in Patients with Metastatic Cancer","volume":"16","author":"Posey","year":"2001","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/CJI.0b013e3181c1f216","article-title":"Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma","volume":"33","author":"Moschos","year":"2010","journal-title":"J. Immunother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-007-9077-0","article-title":"Phase I and Pharmacokinetic Study of Etaracizumab (AbegrinTM), a Humanized Monoclonal Antibody against Av\u03b23 Integrin Receptor, in Patients with Advanced Solid Tumors","volume":"26","author":"Delbaldo","year":"2008","journal-title":"Investig. New Drugs"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cncr.24821","article-title":"A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody against Integrin Alpha(v)Beta(3), + or \u2212 Dacarbazine in Patients with Stage IV Metastatic Melanoma","volume":"116","author":"Hersey","year":"2010","journal-title":"Cancer"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"109487","DOI":"10.1016\/j.cellsig.2019.109487","article-title":"Extracellular Matrix-Cell Interactions: Focus on Therapeutic Applications","volume":"66","author":"Sainio","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Chen, S., Zhang, S., Chen, S., and Ma, F. (2023). The Prognostic Value and Immunological Role of CD44 in Pan-Cancer Study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-34154-3"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Wagner, D.L., and Klotzsch, E. (2022). Barring the Gates to the Battleground: DDR1 Promotes Immune Exclusion in Solid Tumors. Signal Transduct. Target. Ther., 7.","DOI":"10.1038\/s41392-022-00877-4"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Harris, E.N., and Baker, E. (2020). Role of the Hyaluronan Receptor, Stabilin-2\/HARE, in Health and Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103504"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41389-021-00312-3","article-title":"Tumour Cells Express Functional Lymphatic Endothelium-Specific Hyaluronan Receptor in Vitro and in Vivo: Lymphatic Mimicry Promotes Oral Oncogenesis?","volume":"10","author":"Karinen","year":"2021","journal-title":"Oncogenesis"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Hinneh, J.A., Gillis, J.L., Moore, N.L., Butler, L.M., and Centenera, M.M. (2022). The Role of RHAMM in Cancer: Exposing Novel Therapeutic Vulnerabilities. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.982231"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1111\/febs.15776","article-title":"A Guide to the Composition and Functions of the Extracellular Matrix","volume":"288","author":"Karamanos","year":"2021","journal-title":"FEBS J."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Senbanjo, L.T., and Chellaiah, M.A. (2017). CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front. Cell Dev. Biol., 5.","DOI":"10.3389\/fcell.2017.00018"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/mp.52.4.189","article-title":"CD44 Cell Adhesion Molecules","volume":"52","author":"Goodison","year":"1999","journal-title":"Mol. Pathol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10408360290795574","article-title":"CD44 in Cancer","volume":"39","author":"Naor","year":"2002","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.05.050","article-title":"Synergistic Active Targeting of Dually Integrin Av\u03b23\/CD44-Targeted Nanoparticles to B16F10 Tumors Located at Different Sites of Mouse Bodies","volume":"235","author":"Shi","year":"2016","journal-title":"J. Control Release"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/1078-0432.CCR-04-0349","article-title":"Inhibition of Hepatocellular Carcinomas In Vitro and Hepatic Metastases In Vivo in Mice by the Histone Deacetylase Inhibitor HA-But","volume":"10","author":"Coradini","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jconrel.2013.09.008","article-title":"Bioreducible Hyaluronic Acid Conjugates as siRNA Carrier for Tumor Targeting","volume":"172","author":"Yoon","year":"2013","journal-title":"J. Control Release"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1593\/neo.03460","article-title":"Tumor-Targeted Hyaluronan Nanoliposomes Increase the Antitumor Activity of Liposomal Doxorubicin in Syngeneic and Human Xenograft Mouse Tumor Models","volume":"6","author":"Peer","year":"2004","journal-title":"Neoplasia"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ijc.11615","article-title":"Loading Mitomycin C inside Long Circulating Hyaluronan Targeted Nano-Liposomes Increases Its Antitumor Activity in Three Mice Tumor Models","volume":"108","author":"Peer","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_225","first-page":"1561","article-title":"Inhibition of Human Melanoma Growth and Metastasis in Vivo by Anti-CD44 Monoclonal Antibody","volume":"54","author":"Guo","year":"1994","journal-title":"Cancer Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"80046","DOI":"10.18632\/oncotarget.11098","article-title":"First-in-Human Phase I Clinical Trial of RG7356, an Anti-CD44 Humanized Antibody, in Patients with Advanced, CD44-Expressing Solid Tumors","volume":"7","author":"Coveler","year":"2016","journal-title":"Oncotarget"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.18632\/oncotarget.27305","article-title":"Characterizing CD44 Regulatory microRNAs as Putative Therapeutic Agents in Human Melanoma","volume":"10","author":"Kielstein","year":"2019","journal-title":"Oncotarget"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1038\/sj.onc.1204435","article-title":"Soluble CD44 Inhibits Melanoma Tumor Growth by Blocking Cell Surface CD44 Binding to Hyaluronic Acid","volume":"20","author":"Ahrens","year":"2001","journal-title":"Oncogene"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1021\/ja066929m","article-title":"Targeted Drug Delivery Utilizing Protein-like Molecular Architecture","volume":"129","author":"Rezler","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-800180-6.00002-5","article-title":"Discoidin Domain Receptor Functions in Physiological and Pathological Conditions","volume":"310","author":"Leitinger","year":"2014","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_231","first-page":"386","article-title":"DDR1 and DDR2 in Skin","volume":"12","author":"Cario","year":"2018","journal-title":"Cell Adhes. Migr."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/pcmr.12809","article-title":"Discoidin Domain Receptors: A Promising Target in Melanoma","volume":"32","author":"Battistella","year":"2019","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/abbs\/gmv005","article-title":"DDR2 Inhibition Reduces Migration and Invasion of Murine Metastatic Melanoma Cells by Suppressing MMP2\/9 Expression through ERK\/NF-\u03baB Pathway","volume":"47","author":"Poudel","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_234","first-page":"971","article-title":"Downregulation of Discoidin Domain Receptor 2 in A375 Human Melanoma Cells Reduces Its Experimental Liver Metastasis Ability","volume":"26","author":"Badiola","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"e11814","DOI":"10.15252\/emmm.201911814","article-title":"Targeting Discoidin Domain Receptors DDR1 and DDR2 Overcomes Matrix-mediated Tumor Cell Adaptation and Tolerance to BRAF-targeted Therapy in Melanoma","volume":"14","author":"Berestjuk","year":"2022","journal-title":"EMBO Mol. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/22\/1917\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:35:18Z","timestamp":1760114118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/22\/1917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":235,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["cells13221917"],"URL":"https:\/\/doi.org\/10.3390\/cells13221917","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}